NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Receives ‘Buy’ Rating, $14 PT at Aegis Capital
Aegis Capital has issued a ‘Buy’ rating and $14 price target on shares of Novocure’s (NASDAQ: NVCR) stock. The report cites the company’s 151% growth in net revenues from 2015 to 2016 and attributes this growth primarily to Novovure’s Tumor Treating Fields (TTFields) technology. TTTFields have been approved for use in the U.S. and internationally for treating glioblastoma (GBM) patients. The company has big plans for 2017, including continuous market adoption in the U.S. and geographical expansion in Germany and Japan. For more information, visit www.novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer treatment centered…







